Post-PCI Heparin Administration
Routine unfractionated heparin infusion after uncomplicated PCI should be discontinued immediately following the procedure and is no longer recommended. 1
Standard Practice for Uncomplicated PCI
Heparin should only be administered during the procedure itself, with no continuation afterward in uncomplicated cases 1
Post-procedural heparin infusions are specifically not recommended when GP IIb/IIIa inhibitors are used, as this combination significantly increases bleeding risk without improving ischemic outcomes 1
Continuing heparin after uncomplicated PCI is associated with more frequent bleeding events, particularly when combined with platelet GP IIb/IIIa inhibitors 1
A review of patients treated with primary angioplasty and abciximab found that post-procedural heparin (continued for ≥12 hours) did not reduce cardiac or ischemic events but increased total bleeding from 3% to 5.5% 2
Exceptions: When to Consider Continued Anticoagulation
If clinical reasons necessitate extended anticoagulation, subcutaneous unfractionated heparin is preferred over intravenous administration 1
Specific indications for continued anticoagulation include:
- Residual thrombus visible after the procedure 1
- Significant residual dissections that were not adequately treated 1
- High thromboembolic risk conditions requiring bridging therapy 3
When continuation is necessary, subcutaneous administration provides a safer and less costly alternative to intravenous heparin 1
Sheath Management Timing
Femoral sheath removal can be performed 4 hours after the last intravenous dose of enoxaparin or 6-8 hours after the last subcutaneous dose 1
In the modern era with radial access and closure devices, most patients can be safely discharged within the next calendar day after uncomplicated elective PCI 1
Key Pitfalls to Avoid
Do not add additional anticoagulants to patients already receiving one form of anticoagulation (e.g., do not give unfractionated heparin to those who received enoxaparin), as "crossover" between anticoagulants significantly increases bleeding risk 1, 3
Do not use ACT monitoring to guide anticoagulation in patients on low-molecular-weight heparins, as these agents have minimal effect on ACT measurements 1, 3
Avoid the outdated practice from the early 1990s when heparin was continued for 3-10 days post-PCI—this approach is no longer supported and increases complications 1